Group 1 - The company, Jiuzhou Pharmaceutical, stated that it will comply with regulatory requirements for information disclosure in response to investor inquiries on the interactive platform [2]

证券代码：603456 证券简称：九洲药业 公告编号：2026-004 浙江九洲药业股份有限公司 关于使用闲置募集资金进行现金管理到期赎回并 继续进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 现金管理受托方：中国农业银行股份有限公司常熟经济开发区支行（以 下简称"农业银行常熟经济开发区支行"）； 履行的审议程序：浙江九洲药业股份有限公司（以下简称"公司"、"九洲 药业"）于 2025 年 12 月 9 日召开的第八届董事会第十九次会议、第八届审计委 员会第十三次会议，审议通过了《关于使用闲置募集资金进行现金管理的议案》， 同意公司及子公司在保障资金安全及确保不影响募集资金投资项目建设和使用 计划的前提下，使用不超过人民币 10 亿元的闲置募集资金适时购买安全性高、 流动性好的投资产品（包括但不限于结构性存款、定期存款、大额存单、通知存 款、收益凭证及银行或券商理财产品等），不得为非保本型。期限为自董事会审 议通过之日起不超过 12 个月，单笔投资产品的期限不超过 12 个月。本事项无需 提 ...

企业认缴出资总额的 12.987%。根据《上海证券交易所股票上市规则》及《公司 章程》的有关规定，本次对外投资事项无需提交公司董事会、股东会审议批准， 亦不构成关联交易和重大资产重组。 具体内容详见公司于 2025 年 12 月 23 日披露于上海证券交易所官网 （www.sse.com.cn）的《浙江九洲药业股份有限公司关于全资子公司参与投资嘉 兴隆峰创业投资合伙企业（有限合伙）的公告》（公告编号：2025-075）。 证券代码：603456 证券简称：九洲药业 公告编号：2026-003 浙江九洲药业股份有限公司关于全资子公司参与 投资嘉兴隆峰创业投资合伙企业（有限合伙）的进展 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 投资标的名称 | | | 嘉兴隆峰创业投资合伙企业（有限合伙） | | | --- | --- | --- | --- | --- | | 投资金额（万元） | 1,000 | | | | | 投资进展阶段 | 完成 | 终止 | 交易要素变更 | √进展 | | 特别 ...

Core Viewpoint - Jiuzhou Pharmaceutical (603456) emphasizes that its stock performance is influenced by multiple factors including market conditions and sector rotation, while the company remains focused on its core business development to enhance sustainable profitability and governance structure [1] Group 1 - The company aims to actively communicate its core value to the capital market [1] - Jiuzhou Pharmaceutical is committed to creating long-term and stable investment returns for its investors [1]

Core Viewpoint - The report highlights the significant growth and development of China's Contract Research Organization (CRO) industry, driven by a comprehensive policy framework and regulatory reforms that enhance innovation and operational efficiency in the pharmaceutical sector [1][3][9]. Group 1: Industry Overview - The main listed companies in China's CRO industry include WuXi AppTec (603259.SH), Kanglong Chemical (300759.SZ), Tigermed (300347.SZ), Kelaiying (002821.SZ), Zhaoyan New Drug (603127.SH), Jiuzhou Pharmaceutical (603456.SH), Haoyuan Pharmaceutical (688131.SH), Boteng Co., Ltd. (300363.SZ), Chengdu XianDao (688222.SH), and Yaoshi Technology (300725.SZ) [1]. - The CRO industry is recognized as a strategic emerging industry that supports pharmaceutical innovation, transitioning China from a major pharmaceutical market to a strong one [1]. Group 2: Policy Framework - The policy framework for the CRO industry is centered around the National Medical Products Administration (NMPA) and includes collaboration with other regulatory bodies such as the National Health Commission (NHC) and the Drug Administration (CDR) [3]. - Key regulatory measures include the Marketing Authorization Holder (MAH) system, implicit licensing for clinical trials, Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) certifications, and priority review and approval processes [3]. Group 3: Industry Support Policies - National policies provide financial support through initiatives like the "Major New Drug Creation" program, tax reductions for high-tech enterprises, and increased deductions for R&D expenses, which lower operational costs for the industry [6]. - Local governments implement differentiated policies that align with regional industrial characteristics, including subsidies for innovative drug development and funding for CRO platform construction [6]. Group 4: Drug Review Reforms - Recent reforms in drug review processes have significantly improved approval efficiency, reducing the average clinical trial review time from 420 days to 30 days in pilot areas, and addressing a backlog of 22,000 cases [9][12]. - The definition of new drugs has shifted from "China New" to "Global New," aligning with international standards and enhancing the quality of innovation [12]. Group 5: Future Trends - The future of the CRO industry in China is expected to be driven by a robust policy framework, with trends including deeper collaboration in service models, increased application of AI and digital platforms, and a focus on specialized market segments [13]. - The competitive landscape is anticipated to evolve with the rise of domestic leaders and accelerated internationalization, benefiting from improved mechanisms for mutual recognition of clinical trial data [13].

Core Insights - The CRO industry in China is experiencing significant growth, with the market size expected to expand from 90 billion yuan in 2021 to 126 billion yuan by 2024, reflecting a compound annual growth rate (CAGR) of 28%, which is substantially higher than the global average of 10% [13][26] - The industry is characterized by a clear competitive landscape, with WuXi AppTec as the dominant player, achieving revenue exceeding 20 billion yuan, while other key players include Kanglong Chemical, Tigermed, and Kelun Pharmaceutical [17][20] Industry Overview - Contract Research Organizations (CROs) are specialized entities that undertake drug development responsibilities on behalf of pharmaceutical companies, helping to reduce costs and risks while ensuring compliance [1] - The CRO industry is divided into preclinical and clinical segments, with preclinical CROs focusing on drug discovery and safety evaluations, while clinical CROs handle clinical trials and data management [1] Industry Development History - The CRO industry in China began in 1996 with the establishment of the first joint venture, and has evolved from a lack of formal organizations to a competitive landscape dominated by local leaders [9] - The industry has undergone significant changes, including the implementation of Good Clinical Practice (GCP) in 2003 and the introduction of the Marketing Authorization Holder (MAH) system, which has facilitated the growth of CRO services [11] Market Demand and Growth - The number of New Drug Applications (NDA) in China has been increasing, from 210 in 2021 to an expected 320 by 2024, driving demand for CRO services [14] - The global CRO market is projected to grow from 71 billion USD in 2021 to 90 billion USD by 2024, driven by increased healthcare demands due to aging populations and the COVID-19 pandemic [13] Competitive Landscape - The competitive structure of the Chinese CRO industry is categorized into three tiers, with WuXi AppTec leading the first tier, followed by Kanglong Chemical and Tigermed in the second tier, and smaller firms in the third tier [17] - Most companies are diversifying their services to include both CRO and CDMO (Contract Development and Manufacturing Organization) capabilities, enhancing operational efficiency [20] Regional Market Dynamics - The Yangtze River Delta region dominates the CRO market in China, accounting for approximately 43% of the market share, followed by the Beijing-Tianjin-Hebei region at 23% and the Pearl River Delta at 19% [23] Future Outlook - The Chinese CRO market is expected to continue its growth trajectory, potentially exceeding 144 billion yuan by 2028, supported by favorable policies and increasing demand for innovative therapies [26] - Despite challenges such as rising compliance costs and market saturation, the overall outlook remains positive, with expectations of sustained double-digit growth over the next five years [26]

证券日报网讯1月20日，九洲药业（603456）在互动平台回答投资者提问时表示，公司CDMO业务覆盖 全球主要医药市场，服务的客户主要在欧洲、亚太地区。目前海外业务占比80%左右。公司与客户主要 通过签订单次或年度采购合同(协议)来开展合作，具体业务模式与区域详情可参阅公司于上海证券交易 所网站披露的定期报告。 ...

浙江九洲药业股份有限公司 证券代码：603456 证券简称：九洲药业 公告编号：2026-002 关于公司收到化学原料药上市申请批准通知书 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江九洲药业股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）颁发的关于枸橼酸坦度螺酮的《化学原料药 上市申请批准通知书》（通知书编号：2026YS00030），具体情况如下： 一、药品的基本情况 申请事项：境内生产化学原料药上市申请 生产企业：浙江九洲药业股份有限公司，浙江省台州市椒江区外沙路工业区 （外沙路 99 号） 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 二、药品其他相关情况 枸橼酸坦度螺酮是一种抗焦虑药，主要用于各种神经症所致的焦虑状态，如 广泛性焦虑症；原发性高血压、消化性溃疡等躯体疾病伴发的焦虑状态。公司于 2024 年 7 月向国家药品监督管理局药品审评中心（以下简称"CDE"）提交 ...

Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) has received approval from the National Medical Products Administration for the marketing application of Citric Acid Tianeptine, an anti-anxiety medication used for various anxiety states caused by neuroses, such as generalized anxiety disorder, and anxiety states associated with primary hypertension and peptic ulcers [1]. Group 1 - The company has been granted a marketing approval notice for Citric Acid Tianeptine, with the notification number 2026YS00030 [1]. - Citric Acid Tianeptine is primarily indicated for treating anxiety states resulting from various neuroses [1]. - The medication is also applicable for anxiety states associated with physical conditions such as primary hypertension and peptic ulcers [1].

Core Viewpoint - The approval of the citric acid tianeptine raw material drug by the National Medical Products Administration will enhance the company's product portfolio and competitiveness, although it will not have a significant short-term impact on performance [1] Group 1: Product Approval - The company has received the approval notice for the citric acid tianeptine raw material drug from the National Medical Products Administration [1] - The drug is classified as an anti-anxiety medication [1] Group 2: Research and Development Investment - The company submitted the listing application in July 2024 and has invested approximately 6.23 million yuan in research and development [1] Group 3: Market Potential - The global market sales for the drug are projected to reach 390 million USD in 2024 and 750 million USD by 2031 [1] Group 4: Impact on Company Performance - The approval will enrich the company's product structure and enhance competitiveness, but it is noted that there will be no significant short-term impact on performance [1] - There are uncertainties associated with drug production and sales [1]